Turning Point Brands, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Turning Point Brands, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $73.56M | Mar 8, 2018 |
| FY2017 | Sep 30, 2017 | $73.34M | Mar 8, 2018 |
| FY2017 | Jun 30, 2017 | $72.09M | Mar 8, 2018 |
| FY2017 | Mar 31, 2017 | $66.79M | Mar 8, 2018 |
| FY2017 | Dec 31, 2016 | $53.82M | Mar 8, 2018 |
| FY2017 | Sep 30, 2016 | $50.96M | Mar 8, 2018 |
| FY2017 | Jun 30, 2016 | $51.58M | Mar 8, 2018 |
| FY2017 | Mar 31, 2016 | $49.87M | Mar 8, 2018 |
| FY2016 | Dec 31, 2015 | $46.74M | Mar 13, 2017 |
| FY2016 | Sep 30, 2015 | $51.43M | Mar 13, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $264.31M | Mar 2, 2026 |
| FY2024 | Dec 31, 2024 | $52.42M | Mar 6, 2025 |
| FY2024 | Sep 30, 2024 | $50.40M | Mar 6, 2025 |
| FY2024 | Jun 30, 2024 | $50.40M | Mar 6, 2025 |
| FY2024 | Mar 31, 2024 | $48.35M | Mar 6, 2025 |
| FY2024 | Dec 31, 2023 | $47.38M | Mar 6, 2025 |
| FY2024 | Sep 30, 2023 | $47.32M | Mar 6, 2025 |
| FY2024 | Jun 30, 2023 | $46.39M | Mar 6, 2025 |
| FY2024 | Mar 31, 2023 | $41.86M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $49.56M | Feb 28, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.17M | Mar 2, 2026 |
| FY2024 | Dec 31, 2024 | $2.42M | Mar 6, 2025 |
| FY2024 | Sep 30, 2024 | $12.38M | Mar 6, 2025 |
| FY2024 | Jun 30, 2024 | $13.01M | Mar 6, 2025 |
| FY2024 | Mar 31, 2024 | $12.01M | Mar 6, 2025 |
| FY2024 | Dec 31, 2023 | $10.11M | Mar 6, 2025 |
| FY2024 | Sep 30, 2023 | $10.83M | Mar 6, 2025 |
| FY2024 | Jun 30, 2023 | $9.93M | Mar 6, 2025 |
| FY2024 | Mar 31, 2023 | $7.60M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($16.32M) | Feb 28, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.33M | Mar 2, 2026 |
| FY2024 | Dec 31, 2024 | $17.89M | Mar 6, 2025 |
| FY2024 | Sep 30, 2024 | $20.81M | Mar 6, 2025 |
| FY2024 | Jun 30, 2024 | $22.87M | Mar 6, 2025 |
| FY2024 | Mar 31, 2024 | $19.27M | Mar 6, 2025 |
| FY2024 | Dec 31, 2023 | $24.60M | Mar 6, 2025 |
| FY2024 | Sep 30, 2023 | $20.70M | Mar 6, 2025 |
| FY2024 | Jun 30, 2023 | $20.09M | Mar 6, 2025 |
| FY2024 | Mar 31, 2023 | $17.58M | Mar 6, 2025 |
| FY2024 | Dec 31, 2022 | $74.01M | Mar 6, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $900.0K | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.30M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $600.0K | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $600.0K | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $1.10M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.30M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $2.50M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $2.50M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $2.30M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $2.00M | Mar 7, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $168.99M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $122.41M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $104.33M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $103.82M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $127.51M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $125.56M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $109.89M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $94.08M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $75.29M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $56.63M | Mar 7, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.37M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $67.06M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $66.88M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $30.27M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $68.22M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $43.68M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $37.80M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $13.09M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $29.69M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $9.13M | Mar 7, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.53M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $4.62M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $5.71M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $7.83M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $6.16M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $6.14M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $4.82M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $2.27M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $2.02M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $3.21M | Mar 7, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $763.75M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $493.35M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $569.37M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $572.11M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $601.56M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $496.05M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $446.58M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $339.38M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $282.28M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $285.02M | Mar 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $391.77M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $302.97M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $417.36M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $458.73M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $467.84M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $378.56M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $340.00M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $256.75M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $228.95M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $250.96M | Mar 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $150.98M | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | $111.65M | Feb 28, 2024 |
| FY2019 | Dec 31, 2019 | $106.59M | Mar 12, 2020 |
| FY2019 | Dec 31, 2018 | $82.62M | Mar 12, 2020 |
| FY2019 | Dec 31, 2017 | $53.32M | Mar 12, 2020 |
| FY2019 | Dec 31, 2016 | $34.06M | Mar 12, 2020 |
| FY2018 | Dec 31, 2015 | ($81.61M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2014 | ($91.57M) | Mar 8, 2018 |
| FY2016 | Dec 31, 2013 | ($63.43M) | Mar 13, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $136.10M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $135.93M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $136.25M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $136.25M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $162.33M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $159.62M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $154.28M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $145.94M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $134.62M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $134.39M | Mar 7, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $199.66M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $147.16M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $112.44M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $78.69M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $71.46M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $23.65M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($15.31M) | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | ($25.50M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($47.54M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($66.97M) | Mar 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $222.76M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $48.94M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $117.89M | Mar 2, 2026 |
| FY2025 | Dec 31, 2022 | $106.40M | Mar 2, 2026 |
| FY2024 | Dec 31, 2021 | $128.32M | Mar 6, 2025 |
| FY2023 | Dec 31, 2020 | $41.77M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $95.25M | Mar 15, 2023 |
| FY2021 | Dec 31, 2018 | $3.31M | Mar 11, 2022 |
| FY2020 | Dec 31, 2017 | $2.61M | Feb 19, 2021 |
| FY2019 | Dec 31, 2016 | $2.87M | Mar 12, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Mar 2, 2026 |
| FY2024 | Dec 31, 2024 | 0 | Mar 6, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Mar 6, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Mar 6, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Mar 6, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 6, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 6, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Mar 6, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 28, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Mar 2, 2026 |
| FY2024 | Dec 31, 2024 | 0 | Mar 6, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Mar 6, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Mar 6, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Mar 6, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 6, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 6, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Mar 6, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 28, 2024 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.52M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $4.91M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $4.50M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $4.25M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $4.10M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $3.80M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $3.53M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $2.32M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $768.0K | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $0 | Mar 7, 2019 |